Article summary
The Competition and Markets Authority (CMA) has reached a Statement of Objections, provisionally finding that Pfizer and Flynn broke competition law by overcharging the NHS for anti-epilepsy drugs. Pfizer and Flynn allegedly rebranded the drug, so it was not subject to price regulation, leading to NHS spending on the drug to rise from £2m in 2012 to £50m in 2013.
To continue reading this news article, as well as thousands of others like it, sign in with LexisNexis or register for a free trial